Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Negotiation Final Guidance: No More ‘Gag’ Rules, But Other Changes Fall Short Of Hopes

Executive Summary

CMS sends a warning to Medicare Part D plans that beneficiaries should have ‘meaningful’ formulary access to drugs with negotiated prices. However, the guidance does not broaden potential exclusions from negotiation for orphan drugs, to the disappointment of stakeholders.

You may also be interested in...

Stealth Defense: Medicare, IRS Implementation May Weaken Pharma’s Arguments Against IRA

Flexibility included in guidance issued after many IRA lawsuits were filed put some of the arguments industry has made on shakier footing, legal experts explain.

Medicare Director: ‘Bona-Fide’ Generic Marketing Likely Product-Specific For IRA

CMS won’t put a number on ‘bona fide” generic and biosimilar competition. Medicare's head also discussed how it will ensure rebates don’t disadvantage drugs with government-negotiated prices.

Medicare Negotiation Guidance Rebuts Accusations Of Constitutional ‘Due Process’ Violations

The final guidance on the Medicare drug price negotiation program also addresses complaints that the government may violate the uncompensated ‘takings’ clause of the Fifth Amendment of the US Constitution in the way it considers remaining patents and exclusivities for negotiated drugs.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts